Generic Medicine Info
Indications and Dosage
Susceptible infections
Adult: 4-6 mg/kg once daily or in equally divided doses given every 8 or 12 hr. Life-threatening infections: Increase to up to 7.5 mg/kg daily every 8 hr. All doses may be given as IM, slow IV (over 3-5 min) or as 50-200 ml infusion over 0.5-2 hr. Treatment is usually given for 7-14 days.
Child: Premature infants and neonates <1 wk: 6 mg/kg daily in divided doses every 12 hr. Infants and neonates >1 wk: 7.5-9 mg/kg daily in divided doses every 8 hr. Older children: 6-7.5 mg/kg daily in divided doses every 8 hr. Alternative regimen: Neonates <6 wk: 4-6.5 mg/kg daily in divided doses every 12 hr. Older infants and children: 5.5-8 mg/kg daily in divided doses every 8 or 12 hr.

Urinary tract infections
Adult: 150 mg as a single daily dose for 5 days. Complicated UTI: 3-4 mg/kg daily in divided doses every 12 hr. All doses may be given as IM, slow IV (over 3-5 min) or as a 50-200 ml infusion over 0.5-2 hr. Treatment is usually given for 7-14 days.
Renal Impairment
Dose reduction or lengthening of interval between doses may be necessary. Haemodialysis: 50% of initial loading dose is required after dialysis.
Do not mix in the same syringe with penicillins or cephalosporins.
Hypersensitivity to the drug or other aminoglycosides.
Special Precautions
Renal impairment; monitor renal, vestibular and auditory function. Monitor peak serum levels. Myasthenia gravis, parkinsonism, infant botulism; conditions predisposing to ototoxicity and nephrotoxicity. Premature and neonatal infants, dehydration, elderly. Pregnancy and lactation.
Adverse Reactions
Headache, malaise, visual disturbances, disorientation, tachycardia, hypotension, palpitations, thrombocytosis, paraesthesia, rash, chills, fever, fluid retention, vomiting, diarrhoea. Increased blood sugar; increased alkaline phosphatase; increased liver enzymes, bilirubin; increased potassium; other abnormal LFTs; decreased haemoglobin, WBCs and platelets; eosinophilia, anaemia and increase in prothrombin time.
Potentially Fatal: Nephrotoxicity; ototoxicity; anaphylaxis.
Haemodialysis will be beneficial. Institute appropriate supportive therapy.
Drug Interactions
Potentially Fatal: Increased incidence of ototoxicity with ethacrynic acid and furosemide. Increased risk of nephrotoxicity/ototoxicity with cisplatin, bacitracin, polymyxin B, colistin, cefaloridine, amphotericin B, kanamycin, aciclovir, gentamicin, amikacin, sisomicin, tobramycin, neomycin, streptomycin, paromomycin, viomycin and vancomycin. Increased risk of prolonged neuromuscular blockade and respiratory arrest with neuromuscular blocking gents, anaesthetics.
Description: Netilmicin, an aminoglycoside antibiotic, binds to 30S and to some extent to 50S ribosomal subunit of susceptible bacteria disrupting photosynthesis, thus rendering the bacterial cell membrane defective.
Absorption: Rapidly and completely absorbed (IM). Peak plasma concentrations after 0.5-1 hr (IM), 1 hr (IV infusion).
Excretion: Via urine within 24 hr (80% of a dose); 2-2.5 hr (elimination half-life).
Store at 2-30°C. Do not freeze.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Netilmicin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Lotifar
  • Netromycin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in